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Translocation of BCR to Chromosome 9: A New 
Cytogenetic Variant Detected by FISH in Two Ph-Negative, 
BCR-Positive Patients With Chronic Myeloid Leukemia 
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Gerard Grosveld 
Department of Cell Biology and Genetics, Erasmus University ( A H  A.B.. E.S., D.V.d.P., G.G.), Department of Clinical Genetics, 
Academic Hospital Dijkzigt (B.J.), and Dr. Daniel den Hoed Cancer Centre (G.-J.C.). Rotterdam, The Netherlands 
Leukemic cells from two patients with Philadelphia-negative chronic myeloid leukemia (CML) were investigated: I) Cytoge- 
netics showed a normal 46,XY karyotype in both cases, 2) molecular studies revealed rearrangement of the M-BCR region and 
formation of BCR-ABL fusion mRNA with b2a2 (patient I) or b3a2 (patient 2) configuration, and 3) fluorescence in situ 
hybridization (FISH) demonstrated relocation of the 5’ BCR sequences from one chromosome 22 to  one chromosome 9. The 
ABL probe hybridized to  both chromosomes 9 at band q34, while two other probes which map centromeric and telomeric of 
BCR on 22q I I hybridized solely with chromosome 22. For the first time, a BCR-ABL rearrangement is shown to  take place on 
9q34 instead of in the usual location on 22q I I. A rearrangement in the latter site is found in all Ph-positive CML and in almost 
all investigated CML with variant Ph or Ph-negative, BCR-positive cases. The few aberrant chromosomal localizations of 
BCR-ABL recombinant genes found previously were apparently the result of complex and successive changes. Furthermore in 
patient 2, both chromosomes 9 showed positive FISH signals with both ABL and BCR probes. Restriction fragment length 
polymorphism (RFLP) analysis indicated that mitotic recombination had occurred on the long arm of chromosome 9 and that 
the rearranged chromosome 9 was of paternal origin. The leukemic cells of this patient showed a duplication of the BCR-ABL 
gene, analogous to  duplication of the Ph chromosome in classic CML. In addition they had lost the maternal alleles of the 9q34 
chromosomal region. The lymphocytes of patient 2 carried the maternal chromosome 9 alleles and were Ph-negative as 
evidenced by RFLP and FISH analyses, respectively. Genes Chrorn Cancer 8:237-245 (1993). 0 1993 Wiley-Liss, Inc. 
INTRODUCTION 
T h e  t(9;22)(q34;ql l ) ,  i.e., the Philadelphia (Ph) 
translocation, is the cytogenetic hallmark of 
chronic myeloid leukemia (CML) in which it is 
observed in more than 90% of the cases. Molecu- 
larly, the translocation results in the formation of a 
chimeric BCR-ABL gene that encodes a chimeric 
BCR-ABI, protein. T h e  chromosome 22 break- 
point is generally, but not exclusively, located in a 
5 kb BgIII fragment of the BCR gene, the so-called 
major breakpoint cluster region (M-BCR). De- 
pending upon the position of the breakpoint within 
M-BCR, two exons (b2 and b3) can be spliced to 
exon a2 of the ABL gene to form the chimeric BCR- 
ABL niRNA (Heisterkamp et al., 1985). 
Cytogenetic variants of the Ph translocation can 
be studied by Southern blotting to demonstrate a 
rearrangement in the M-BCR or by RNA-PCR to 
show the specific junction type, b2a2 or b3a2, in 
the mRNA of the recombinant gene. We and oth- 
ers have demonstrated that the cytogenetic variants 
of the Ph (simple, complex, masked Ph) resulted 
in the same molecular BCR-ABL recombination as 
in the standard Ph (Hagemeijer et al., 1984, 1985; 
Bartram et al., 1985; Morris et al., 1988; Dube et 
al., 1989). 
A small number of patients with C M L  do not 
show any evidence of a Ph chromosome. T h e  ma- 
jority of these have a normal karyotype, some have 
abnormalities involving chromosome 9 at band q34 
or other changes, but invariably the chromosome 
22 appears normal. When investigated by molecu- 
lar means, some cases show evidence of an M-BCR 
rearrangement or a BCR-ABL mRNA. T h e  remain- 
ing cases are Ph-negative cytogenetically and mo- 
lecularly and show slightly different pathological 
features and shorter survival (Martiat et al., 1991; 
Van der Plas et al., 1991). 
Metaphase cells from Ph-negative but molecu- 
larly M-BCR-positive CML patients have been 
studied using in situ hybridization (ISH) with 
probes specific for the ABL and BCR genes. This 
technique has demonstrated co-localization of the 
probes and by inference the genes map to the same 
chromosomal band. In at least six cases, transloca- 
tion of ABL to chromosome 22 was demonstrated 
(Ganesan et al., 1986; Morris et al., 1986; Dreazen 
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et al., 1987; Inazawa et al., 1989). We report 2 
CML patients with a normal leukemic karyotype 
who showed the recombined BCR-ABL gene lo- 
cated in chromosome 9 at band q34. In one of the 
cases, there was evidence for somatic recombina- 
tion giving rise to a population with two chromo- 
somes 9 carrying the BCR-ABL gene. 
CASE REPORTS 
Patient I 
J.W. was admitted with a recent history of 
weight loss (5 kg) and appearance of tumors on the 
head. There were no complaints of dyspnoea, diz- 
ziness, or headache. Physical examination showed 
a pale 22-year-old male with a congenital malfor- 
mation of the thorax and right hand, with three 
tumors on his head with a size of 2 x 3 crn each, 
and enlarged lymph nodes in the submandibular 
and axillar region (3  X 3 cm). There was spleno- 
megaly 8 cm below the left costal margin but no 
hepatomegaly. Fundoscopy showed dilated tortu- 
ous blood vessels and numerous hemorrhages in 
the retina. Laboratory investigations revealed a he- 
moglobin of 4.9 mmol/l, platelets 263 x 109/1, and 
leucocytes of 405 X 109/1 with 13% basophils, 3% 
eosinophils, 7% band forms, 32% neutrophils, 12% 
promyelocytes, 19% myelocytes, and 14% 
metamyelocytes. Serum LDH was 900 U/I. Leu- 
cocyte alkaline phosphatase was absent. T h e  bone 
marrow was hypercellular with a myeloid/erythroid 
ratio of 8: 1, a prominent increase in basophils, and 
a normal karyotype. Treatment with leukapheresis 
and hydroxyurea produced a good response ini- 
tially. Two months later the patient developed 
thrombocytosis and became unresponsive to hy- 
droxyurea. Bone marrow examination showed a 
lymphoblastic crisis and an abnormal karyotype, 
47,XY,+mar (JSCN 1991). T h e  patient was 
treated with multiple combination chemotherapy 
regimens without success. He  died 10 months after 
diagnosis. 
Patient 2 
W.K. was referred to the hospital because of hy- 
perleucocytosis found at a routine laboratory anal- 
ysis. He had a slight prostatism and a recent loss of 
weight (5 kg). Physical examination showed a 
healthy, 49-year-old male with splenoniegaly 6 crn 
below the left costal margin. Laboratory investiga- 
tions revealed a hemoglobin of 6.8 mmol/l, plate- 
lets 156 x 109/1, and leucocytes 322 x lO"/l. 
Microscopic examination of a peripheral blood 
smear showed myeloid cells at all stages of devel- 
opment with some hypersegmented forms. There 
were 2% basophils, 3% eosinophils, 15% bands, 
48% neutrophils, 2% blasts, 7% promyelocytes, 
17% myelocytes, and 6% metamyelocytes. Serum 
L D H  was 1,017 U/I. Leucocyte alkaline phos- 
phatase activity was absent. T h e  bone marrow was 
hypercellular with a myeloid/erythroid ratio of 
40: 1, no increase in bone marrow blasts, and a nor- 
mal karyotype. 
Treatment with hydroxyurea resulted in a reduc- 
tion in spleen size and peripheral leucocyte counts. 
T h e  patient has been followed for about 9 months. 
His disease is still in chronic phase but is very 
difficult to stabilize with highly variable WBC. He 
has an HLA-identical MLC-negative brother, and 
an allogeneic bone marrow transplantation is 
planned. 
MATERIALS AND METHODS 
Patient Material and Cytogenetics 
Bone marrow and blood cells from both patients 
were obtained at diagnosis and at various times 
during the course of the disease. Cytogenetic anal- 
ysis was carried out according to our standard pro- 
cedure (Hagemeijer et al., 1979). Diagnostic rna- 
terial of both cases was kept frozen in 10% DMSO 
in liquid N, and thawed for molecular studies. 
New cultures of thawed diagnostic bone marrow 
from patient 1 were used for FISH analyses. T h e  
same cultures were used for cytogenetic and in .siru 
hybridization studies of patient 2. 
Southern Blotting 
DNA was extracted from bone marrow cells of 
both patients and from a normal thymus. T o  detect 
a rearrangement of the M-BCR, Southern blots 
containing DNA, digested with BcoRI, BarnHI, 
HindIII, and BgIII were hybridized to three 
probes: 1) 5' BCR: a 2 kb BglII-Hind111 fragment, 
2) 3' BCR, a 1.2 kb HindIII-BgllI fragment, and 3) 
the universal BCR probe (Oncogene Sciences, Mi- 
neola, NY). 
T o  perform RFLP analysis of chromosome 9, 
DNA from bone marrow and peripheral blood from 
patient 2 was digested with BstXI, TaqI, and 
HindIII, blotted and hybridized with probes 26p 
(locus D9S5, obtained from ATCC, Rockville, 
MD), hAKlB3.25 (AK1, N.T.  Bech-Hansen), 
ASSgl (ASS, ATCC), MCT136 (D9S10, Y. Naka- 
mura), and EFD126.3 (D9S7, Y. Nakamura). 
DNA of the patient's mother, obtained from pe- 
ripheral blood, was similarly digested with TaqI 
and HindIII, blotted, and hybridized with 
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EFD 126.3, hAKlB3.25, and ASSGl, sequentially. 
T h e  parental origin of each allele was deduced 
from the haplotypes. 
RNA-PCR Analysis 
Total RNA was extracted by the guanidine-thio- 
cyanate method (Chomczynski and Sacchi, 1987). 
lising antisense ABL primer a3 and reverse tran- 
scriptase (Superscript, Gibco BRL, Grand Island, 
NY), cDNA was obtained and subsequently ampli- 
fied using 2.5 units Taq polymerase (Boehringer 
Mannheim, Indianapolis, IN) in the presence of 
sense primers of BCR gene b2 and 1st exon e l .  
T h e  technique, primers, and detection oligonucle- 
otides were as described by Hermans e t  al. (1988). 
As internal positive control in the PCR, an ABL 
fragment was amplified (Van der Plas et al., 1989). 
Twenty-four cycles of amplification were per- 
formed. T h e  samples were electrophoresed and 
transferred to nylon filters (Zetaprobe), which were 
hybridized to 32P end-labeled oligonucleotides, 
spanning the el-az and bZ-a2 and b3-a2 junctions. 
After hybridization the blots were washed and ex- 
posed to Fuji XR films (Tokyo, Japan). 
Fluorescence In Situ Hybridization (FISH) 
T h e  probes were labeled by standard nick trans- 
lation using either biotin-16-dUTP or digoxigenin- 
1 1-dUTP (both from Boehringer-Mannheim). In 
double color FISH a mixture of two differently 
labeled probes was used. After heat denaturation, 
25 to 50 ng of probe was preannealed with 10 p,g of 
Cot-1 DNA for 1-3 hr at 37°C. T h e  hybridization 
mixture contained the probes and Cot-1 DNA in 
50% formamide, 10% dextran-sulphate in 2 x 
SSCP. All details concerning pretreatment of 
slides, hybridization, washing, and immunochem- 
ical detection were as reported (Arnoldus et al., 
1990). T h e  probes used were 1) Cos-ABL-18, a 40 
kb fragment containing the 3’ coding region of the 
human ABL gene, 2 )  Cos-BCR-16 containing a 32 
kb fragment representing most of the first exon and 
part of the first intron of BCR, 3) Cos X 3.1, a 
cosmid containing sequences of the constant part 
of the ZGL gene that maps on chromosome 22 cen- 
tromeric of BCR, 4) 40D2, a cosmid containing se- 
quences that map on 22ql l  a few megabases telo- 
meric of the BCR gene, and 5) pHUR98, a satellite 
111 DNA probe, was used at low concentration (5 
ng/lO PI). This probe recognizes specifically the 
polymorphic paracentromeric region of chromo- 
some 9. It  was used to facilitate the identification 
of chromosomes 9 in the metaphase cells. When- 
ever possible, 20 to 35 metaphases were scored 
Figure I. Partial karyotype showing apparently normal pairs of chro- 
mosomes 9 and 22 of patient I (A) and patient 2 (B). R-bands with 
acridine orange. 
with each probe. Chromosomes were identified by 
DAPI banding or by combined hybridization with 
centromere specific probes. 
RESULTS 
Cytogenetics 
Patient I showed, at diagnosis, a normal karyo- 
type (46,XY) in 44 bone marrow metaphase cells. 
In particular, using various banding techniques, no 
structural aberrations were seen on chromosomes 9 
and 22 (Fig. 1A). Three months later, during blast 
crisis, the 32 karyotyped metaphases showed 47 
chromosomes, with an extra marker that looked 
like a slightly elongated chromosome 21. T h e  re- 
maining 46 chromosomes appeared structurally 
normal. After blast crisis therapy, the percentage of 
cells with 47 chromosomes regressed but never dis- 
appeared. Patient 2 bone marrow cells showed a 
normal 46,XY karyotype in all 32 metaphase cells 
analyzed at diagnosis (Fig. 1B). 
Molecular Investigations of BCR and ABL 
T h e  results of Southern blotting analysis are 
given in Table 1.  T h e  presence of aberrant restric- 
tion fragments in the various digests indicated re- 
arrangement of the M-BCR in both patients. 
T h e  results of PCR amplification of cDNA fol- 
lowed by hybridization to breakpoint specific oli- 
gonucleotides are shown in Figure 2 .  A 319 base 
pair (bp) fragment corresponding to b2-aZ joining 
in the BCR-ABL mRNA was found in patient 1. A 
394 bp fragment corresponding to b3-a2 joining 
was found in patient 2 .  As expected, neither b2-a2 
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TABLE I. Approximate Size in of Restriction Fragments Observed in DNA of Patients I and 2 A f te r  
Southern Hybridization With M-BCR Probesa 
Patient I Patient 2 
Restriction Fragment Probes 5' BCR 3' BCR Universal BCR Universal BCR 
6glll 
6ornHl 
Hindll I 
EcoRl 
~~ 
6, 4.8b 4.8b. 3.5 6, 4.8b, 3.5, 2.3b, ) . I b  8', 4.8+, 2.3b, I . Ib  
14. IZb 6. 3.2b N.D. 12b. lod. 3.2b 
N.D. N.D. N.D. 
N.D. N.D. N.D. 
15, 9.5b, 4.6b 
I8  kbb 
"N.D. = no data due t o  incomplete digestion of DNA. 
bGermline fragment also present in control DNA, aberrant fragments in bold. 
'Aberrant fragment strongly expressed. 
dVery weakly expressed aberrant fragment. 
Figure 2. RNA-PCR analysis of patient I (lane I). patient 2 (lane 
Z), a Ph-positive CML positive control (lane 3), and a normal healthy 
control (lane N). The empty lane is a negative control using distilled 
water instead of RNA. A: amplification of ABL internal fragment; B 
amplification of BCR-ABL junction fragment; C. hybridization with junc- 
tion specific oligonucleotides. M = DNA size markers. 
nor b3-a2 joining was detected in the leucocytes of 
a healthy control. 
Fluorescence In Situ Hybridization (FISH) 
Most of the FISH analyses were performed with 
probes labeled with biotin and detected with avi- 
din FITC. Using fluorescene microscopy, the yel- 
low-green hybridization signal was easily detected 
on the red background of propidium iodide stained 
chromosomal DNA. 
T h e  results are illustrated in Figures 3 and 4 and 
summarized in Table 2 .  In a normal control, the 
ABL probe hybridized to both chromosomes 9 a t  
band q34 and the BCR probes to both chromo- 
somes 22 .  In CML controls with a standard t(9;22), 
Cos-ABL-18 hybridized to the normal 9 at band 
q34, and the 22q- and Cos-BCR-16 hybridized to 
22 and 22q- (data not shown). In both patients the 
ABL probe hybridized to both chromosomes 9 a t  
band q34, as it did in normal individuals. T h e  BCR 
probe in patient 1 showed two signals, one on chro- 
mosome 9 and one on chromosome 22. In patient 
2, three BCR signals were seen in most 
metaphases, on one chromosome 22 and on both 
chromosome bands 9q34 (Fig. 4). T h e  aberrant lo- 
calization of BCR on chromosome 9 was confirmed 
independently in both patients using cohybridi- 
zation of the BCR probe and pHUR98, a probe 
specific for the paracentromeric region of chromo- 
some 9. 
In both patients, the two remaining probes that 
map centromeric and telomeric of BCR on chromo- 
some 22 hybridized exclusively to both chromo- 
somes 22 .  These results are best interpreted by 
suggesting an insertion of the 5' part of the BCR 
gene within or at the 5' side of the ABL gene on 
one chromosome 9. In patient 2 ,  both chromo- 
somes 9 showed BCR as well as ABL signals in 17 
of the 20 metaphases analyzed. This could be due 
to duplication of the rearranged chromosome 9 
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Figure 3. Partial metaphases from patient I showing the results of FISH. A. Cos-BCR- I6 probe shows 
clear hybridization signal on one chromosome 22 and one chromosome 9. 8: DAPl staining of the same 
metaphase cell. C: Cos-ABL- I8  probe on two chromosomes 9. D: Cos A 3. I on both chromosomes 22 and 
E: Cos-40D2 also on both chromosomes 22. 
with loss of the normal 9 or mitotic recombination 
of part of chromosome 9. Whatever the mecha- 
nism, it resulted in duplication of the BCR-ABL 
gene, as often seen in standard t(9;22) CML with 
an extra Ph chromosome. In 3 out of 20 cells from 
patient 2 ,  only one chromosome 9 was marked with 
the BCR probe. This could be due to a lack of 
sensitivity of the hybridization experiment or it 
could indicate the presence of a cell population 
with one normal and one rearranged chromosome 
9, as in patient 1, whereas the majority of the cells 
concdined two rearranged chromosomes 9. Two- 
color hybridization of BCR (FITC) and ABL 
(TRITC) probes on interphase nuclei from patient 
2 showed many cells with two bicolored (TRITC/  
FITC) spots and a third F I T C  signal confirming 
242 HAGEMEIjER ET AL. 
Figure 4. Partial metaphases from patient 2 showing the results of FISH. A Cos-ABL- 18 probe on both 
chromosomes 9. 6: DAPl staining of the same metaphase. C: Co-hybridization of pHUR98 (chromosome 9) 
and Cos-BCR- I6  probe showing 3 BCR signals on both chromosomes 9 and one 22. D: Cos A 3. I and E: 
Cos 40D2, both probes on both chromosomes 22. 
the findings on metaphase chromosomes. Two  
months after the start of therapy, when the periph- 
eral WBC had dropped to 12 x 109/1 and the dif- 
ferential count showed 18% lymphocytes, a PHA 
stimulated blood culture was done and metaphase 
chromosomes were hybridized to the probes. T e n  
metaphase cells were analyzed for each probe, 
which showed a hybridization pattern correspond- 
ing to normal, non-rearranged cells, i.e., ABL on 
both chromosomes 9, BCR, X 3.1,  and 40D2 on 
both chromosomes 22 (Table 2). This  indicated 
absence of BCR-ABL rearrangement in T-lympho- 
cytes, as expected. A control hybridization was 
done on bone marrow cells, 6 months after the 
beginning of therapy. Three  signals for BCR were 
seen in 15 out of 15 metaphases and in 78% of the 
nuclei, indicating the persistence of a double BCR- 
ABL recombination in a substantial percentage of 
marrow cells. 
RFLP Analysis 
To further investigate the mechanism by which 
both chromosomes 9 are involved in Ph rearrange- 
ment in patient 2,  RFLP analysis of polymorphic 
markers of 9q was performed on bone marrow and 
blood from the patient as well as on blood from his 
mother. At the time of study, blood from the  pa- 
tient contained a mixture of leukemic cells and 
normal lymphocytes. Material from the father was 
not available. T h e  results showed a partial loss of 
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TABLE 2. Number of Mitoses Scored and Chromosome Localization of FlTC Signals Obtained After Hybridization of Metaphase 
Chromosomes From the Two Ph(-) CML Patients 
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~~ ~ 
Patient I 
Bone marrow at diagnosis 
Patient 2 Patient 2 
Bone marrow at diagnosis Lymphocyte culture 
~~ ~ ~ 
Probes 9” 9 22 22 
COS-ABL- I8 22b 22 0 0 
COS-BCR- I 6  35 0 35 0 
Cos A 3.1 0 0 16 16 
40D2 0 0 36 36 
9 9 22 22 9 9 22 22 
25 25 0 0 10 10 0 0 
20 17 20 0 0 0 10 10 
0 0 20 20 0 0 10 10 
0 0 20 20 0 0 10 10 
~~ ~ ~ 
’9 means 9q34 and 22 means 22q I I. 
bNumber of mitoses showing a positive FITC signal on the given chromosome. 
some maternal chromosome 9 alleles (Fig. 5; Table 
3). T h e  proximal marker 26p retained heterozygos- 
ity, while the more distal markers hAKlB3.25, 
ASSgl, MCT136, and EFD126.3 showed homozy- 
gosity (or hemizygosity) in the bone marrow cells 
and the majority of blood cells (Fig. 5, lanes A and 
B, respectively). In particular, the maternal alleles 
for ASSGl and EFD126.3 markers were absent 
from the patient’s bone marrow. This can be ex- 
plained by assuming that in the leukemic cells a 
mitotic recombination had occurred between 26p 
and AK1, resulting in homozygosity of all paternal 
alleles on chromosome 9, at band q34, including 
duplication of the BCR-ABL gene. These results 
also suggest that the paternal chromosome 9 was 
involved in the formation of the BCR-ABL hybrid 
gene in this patient. 
DISCUSSION 
Analyses of leukemic cells from 2 CML patients 
showed a normal karyotype but molecular changes 
corresponding to a Ph translocation. FISH with 
cosmids specific for 3’ ABL and 5’ BCR showed 
aberrant localization of 5’ BCR sequences on chro- 
mosome band 9q34. As evidenced by RNA-PCR, a 
classic RCR-ABL mRNA was encoded in both 
cases. This is to the best of our knowledge the first 
time that relocation of 5’ BCR sequences to chro- 
mosome 9 is documented. A number of other cases 
of CML with an apparently normal karyotype have 
been investigated. In at least six cases, transloca- 
tion or insertion of ABL sequences on one chromo- 
some 2 2  within the BCR gene was demonstrated 
(Morris et al. 1986, 1990; Ganesan et al., 1986; 
Dreazan et al., 1987; Inazawa et al., 1989), 
whereas in at least three cases RCR and ABL se- 
quences were shown to be located on different 
chromosome arms like l p  or 2Op (Van der Plas et 
al., 1989; Morris et al., 1991). T h e  latter situation 
Figure 5. Restriction fragment length polymorphisms detected by 
the probes 26p (BstXI). MCTl36 (Hindlll), and EFD126.3 (Taql). Lanes 
A bone marrow DNA from patient 2; B: DNA from peripheral blood, 
obtained from patient 2 after treatment; C: pooled DNA from nine 
controls ( I  8 different chromosomes, displaying all possible alleles); D: 
DNA from the mother of patient 2; E.F: DNA from two controls, 
known to have alleles 1-3 and 2-4 at EFD 126.3. The Hindlll polymor- 
phism detected by MCTl36 is a still unpublished RFLP with fragment 
sizes of 2.3 and 2.5 kb. Analysis of 100 unrelated individuals revealed 
complete linkage disequilibrium between the Hindlll RFLP and the al- 
ready published Pstl RFLP at this locus. The autoradiographs clearly show 
retention of heterozygosity at 26p and homozygosity in lane A detected 
by MCT136 and EFD126.3. The unequal ratio of both alleles in lane B 
detected by MCT I 36 and EFD 126.3 indicates that even after treatment 
the myeloid cells st i l l  contain the BCR-ABL duplication. 
is more often observed when changes of 9q34 are 
visible cytogenetically (Bartram et al., 1985; 
Kurzrock et al., 1986; Van der Plas et al., 1989). In 
the latter cases there are often residual 3‘ BCR 
sequences on the der(9) that suggest occurrence of 
at least two successive translocations, i.e., t(9;22) 
followed by translocation between the der( 22) and 
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TABLE 3. Genotypic Data of Chromosome 9 Markers From Patient 2 and His Mother" 
Genotype 
Chromosome Patient 2 Patient 2 Mother 
Probe localization Enzyme (blood) (bone marrow) (blood) 
26 P 9q 12-q13 BstXl 1-2 1-2 n.a. 
hAK I 63.25 9q34. I Taql 1-2 1-1 1-2 
ASSg I 9q34. I Hind I I I 1-2 1 - 1  2-2 
MCT I 36 9q34.3 Hind1 I I 1-2 1-1 n.a. 
EFD 126.3 9q 34 Taql 2-4 2-2 1-4 
"Markers are listed in chromosomal order from centromere M telomere. Marker ASSgl maps within I cM from 
ABL (Povey et al., 1992). Bone marrow cells were obtained at diagnosis; peripheral blood was drawn 6 months 
after start  of therapy and contained 12% of lymphocytes and 88% of myeloid cells. n.a.-not analyzed. 
a third chromosome, displacing the BCR-ABL chi- 
meric gene and restoring an apparent integrity of 
chromosome 22 at the cytogenetic level. 
Our observations in the two cases reported here 
suggest that BCR sequences were inserted at the 5' 
side of the ABL gene. But investigation at the ge- 
nomic level using pulsed-field gel electrophoresis 
(PFGE) or cloning and sequencing have not been 
performed and we cannot exclude the possibility of 
two successive translocations, first a classic t(9;22) 
followed by a second translocation between both 
derivatives, i.e., 9q+  and 22q-, masking the first 
chromosomal exchange. 
FISH with specific cosmid probes is a highly 
efficient tool for the study of such cases: they pro- 
vide clear hybridization signals on both chromatids 
of the target chromosomes which are clearly distin- 
guishable from background hybridization signals. 
Furthermore, all mitotic cells are informative. Us- 
ing two-color FISH it is possible to see the conflu- 
ence of labeled sequence on the same chromosome 
band, while the homologous chromosome carries 
only one of the genes. This is particularly impor- 
tant in cases where rearranged chromosomes are 
not morphologically distinguishable from their nor- 
mal homologs. 
T h e  cases studied here should make cytogenet- 
icists aware of the fact that use of FISH with only 
the ABL probe to analyze Ph-negative C M L  can be 
misleading: FISH of ABL probe in our two cases 
conformed with a normal karyotype. Hybridization 
of 5' BCR sequences indicated abnormality, as did 
the molecular studies. 
Duplication of the Ph is a frequent evolutionary 
event in CML. In patient 2 ,  we showed that du- 
plication occurred by somatic crossing over of the 
long arm of chromosome 9 and loss of maternal 
alleles. Reeve et al. (1988) described a similar phe- 
nomenon, i.e., loss of germline BCR sequences 
and duplication of rearranged BCR sequences as 
well as acquired homozygosity of ZGL sequences. 
Other genes on chromosome 22 were not investi- 
gated. In our patient 2, duplication of the BCR- 
ABL allele allowed the use of RFLP analysis. Our 
study indicated that the rearranged chromosome 9 
was of paternal origin, which is in line with the 
results reported recently by Haas et al. (1992). 
These authors analyzed the cytogenetically poly- 
morphic regions on 9 q l l  and 22p l l  in 15 CML 
patients with t(9;22) and their parents. T h e  9q+  
was shown to be of paternal origin and the 22q- of 
maternal origin. In our patient 2 ,  the proximal part 
of the duplicated chromosome 9 (marker 26p, Fig. 
5) retained heterozygosity and hence was of mater- 
nal origin. 
T h e  difference in band intensity for MCT136 
and EFD126.3 in the peripheral blood sample 
(Fig. 5, lane B) reflects the abnormal ratio between 
myeloid cells carrying the duplication and the 
number of lymphocytes, which have been shown 
by FISH (Table 2 )  not to carry the BCR-ABL hy- 
brid gene and thus to contain both maternal and 
paternal alleles. 
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